Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 9/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.57 |
| ▸ | CFTR | P13569 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1466529 | 0.89 | NR4A2 (0.65) | NR4A2MEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL6029993 | 0.86 | MEN1 (0.58) | NR4A2MEN1ALDH1A1CYP1A2HPGD | |
| Hydrochloric Acid SCHEMBL14487414 | 0.85 | MEN1 (0.56) | NR4A2MEN1ALDH1A1CYP1A2HPGD | |
| SCHEMBL29644277 | 0.83 | ALDH1A1 (0.83) | MEN1ALDH1A1CYP1A2HPGDALOX12 | |
| SCHEMBL10253551 | 0.83 | ALDH1A1 (0.83) | MEN1ALDH1A1CYP1A2HPGDALOX12 | |
| SCHEMBL29644278 | 0.81 | MEN1 (0.65) | MEN1ALDH1A1CYP1A2HPGDALOX12 | |
| SCHEMBL3629228 | 0.81 | ALDH1A1 (0.65) | MEN1ALDH1A1CYP1A2HPGDALOX12 | |
| SCHEMBL2133676 | 0.81 | MEN1 (0.65) | MEN1ALDH1A1CYP1A2HPGDALOX12 | |
| SCHEMBL4235843 | 0.81 | NR4A2 (0.70) | NR4A2CREBBPNPC1MAPTMAP2K1 | |
| SCHEMBL3174159 | 0.80 | ALDH1A1 (0.60) | NR4A2MEN1ALDH1A1CYP1A2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993523-B2 | Dimeric IAP inhibitors | NOVARTIS AG (CH) | 2015-03-31 | — | — | US | disclosed |
| CN-103347874-B | dimeric IAP inhibitors | NOVARTIS AG (CH) | 2014-10-29 | — | — | CN | disclosed |
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| EP-2651919-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-103347874-A | Dimeric iap inhibitors | NOVARTIS AG | 2013-10-09 | — | — | CN | disclosed |
| WO-2012080271-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130309247-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | NR4A2 3995/4885MEN1 931/4885ALDH1A1 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.